Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

NCT02335424 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

374

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

BIOLOGICAL: pembrolizumab

Sponsor

Merck Sharp & Dohme LLC